Financier Carl Icahn said he has voluntarily dismissed a lawsuit filed against Amylin Pharmaceuticals Inc after talking with the biotech company's Chief Executive Officer Daniel Bradbury.
Icahn, whose 8.94 percent stake has made him Amylin's third-largest shareholder, filed the suit earlier this month after the maker of diabetes drugs Byetta and Bydureon was reported to have rejected a $3.5 billion unsolicited takeover bid from Bristol-Myers Squibb Co.
Continue Reading Below
Icahn said in a regulatory filing on Wednesday that he "continues to strongly believe that the company should be sold at this time."
The lawsuit had sought to block enforcement of a bylaw that prevented the billionaire investor from launching a proxy fight.
(Reporting By Deena Beasley; Editing by Gerald E. McCormick)